Skip to content
Open access · CC-BY via OpenAlex

Inhibition of the PI3K/AKT/mTOR pathway in pancreatic cancer: is it a worthwhile endeavor?

Ouissam Al Jarroudi, Hind Chibani, Sami Aziz Brahmi, Afqir Said

Therapeutic Advances in Medical Oncology · 2024 · ▲ 17 citations

Abstract

Pancreatic cancer (PC) is an aggressive disease that is challenging to treat and is associated with a high mortality rate. The most common type of PC is pancreatic ductal adenocarcinoma (PDAC), and the existing treatment options are insufficient for PDAC patients. Due to the complexity and heterogeneity of PDAC, personalized medicine is necessary for effectively treating this illness. To achieve this, it is essential to understand the mechanism of PDAC carcinogenesis. Targeted therapies are a promising strategy to improve patient outcomes. Aberrant activation of the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">rapamycin(definition) (PI3K/AKT/mTOR) signaling pathway plays a crucial role in PC pathogenesis, from initiation to progression. This review provides a comprehensive overview of the current state of knowledge regarding the PI3K pathway in PDAC, summarizes clinical data on PI3K pathway inhibition in PDAC, and explores potential effective combinations that are a promising direction requiring further investigation in PDAC.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1177/17588359241284911
Canonical
link ↗
Fetched
2026-11-07 MST

Cite this

APA
Jarroudi, O.A., Chibani, H., Brahmi, S.A., &amp; Said, A. (2024). Inhibition of the PI3K/AKT/mTOR pathway in pancreatic cancer: is it a worthwhile endeavor?. <em>Therapeutic Advances in Medical Oncology</em>. https://doi.org/10.1177/17588359241284911
Vancouver
Jarroudi OA, Chibani H, Brahmi SA, Said A. Inhibition of the PI3K/AKT/mTOR pathway in pancreatic cancer: is it a worthwhile endeavor?. Therapeutic Advances in Medical Oncology. 2024. doi:10.1177/17588359241284911.
BibTeX
@article{ouissam2024Inhibi, title = {Inhibition of the PI3K/AKT/mTOR pathway in pancreatic cancer: is it a worthwhile endeavor?}, author = {Ouissam Al Jarroudi and Hind Chibani and Sami Aziz Brahmi and Afqir Said}, journal = {Therapeutic Advances in Medical Oncology}, year = {2024}, doi = {10.1177/17588359241284911}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings